non-small cell lung cancer
Conditions
Interventions
Gold Standard:(1) Diagnosis of non-small cell lung cancer patients by histopathology and cytopathology.
(2) Other clinical indicators such as imaging and etiology are clearly indicated as non-small ce
Index test:(1) Compare and study the results of the constructed sensing platform with the judgment results of clinical reference standards. Instrument: Automatic detection device for circulating tumor
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Collect clinical blood from patients with advanced EGFR sensitive mutation NSCLC and treated with third-generation EGFRTKI. (2) Standardize sample processing. (3) Control variables are uniformly detected using a sensing platform. (4) By using a sensing platform to detect the presence of drug-resistant cells per milliliter of blood, it is determined that the patient has developed drug resistance.
Exclusion criteria
Exclusion criteria: (1) Do not collect hemolytic samples (2) People with acute and severe illness, those with a history of surgery in the past six months, and those with blood sickness are not eligible to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of drug-resistant circulating tumor cells in non-small cell lung cancer;specificity;sensitivity; | — |
Countries
China
Contacts
Public ContactLin Ping
West China Hospital, Sichuan University
Outcome results
None listed